Corporate Information

Canbex was established to develop the VSN compound series, a drug development platform with potential applications in a wide range of therapeutic areas due to its mechanism of action. The lead molecule of the series, VSN16R, is in a Phase II trial for the treatment of spasticity in people with multiple sclerosis.

The company operates on a capital-efficient, low-burn virtual basis. In addition to its pioneering scientific founders, Canbex has assembled a highly skilled and experienced team of managers and advisors. Development activities are carried out through professionally managed outsourcing to well-established CROs and CMOs.

Operational Management

Dr Jesse Schulman, Chief Executive Officer
Dr Keith Powell, Chairman
Dr Jill Makin, Head of Manufacturing
Dr Allison Morgan, Head of Clinical Operations

Scientific and Clinical

Professor David Selwood, (UCL) Chief Scientific Officer
Professor David Baker, (Barts and The London) Head of Biology
Professor Gavin Giovannoni, (Barts and The London) Clinical Advisor

CROs and CMOs

Dalton Pharma Services (Toronto) – GMP Manufacturing
Pharm-Olam (UK) – Phase IIa
Quintiles (London) – Phase I
Charles River Labs (Edinburgh) – Preclinical studies

Board Members

Dr Keith Powell, Chairman
Dr Jesse Schulman, CEO
Dr Lars Gredsted, Director
Roel Bulthuis, Director
Dr Andrew Wood, Director
Mr Dean Slagel, Director